Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Nebulized opioids use in COPD.

Pamela A Foral1, Mark A Malesker, Guillermo Huerta

  • 1Creighton University School of Pharmacy and Health Professions, 2500 California Plaza, Omaha, NE 68178, USA. pforal@creighton.edu

Chest
|February 11, 2004
PubMed
Summary

Nebulized opioids are not recommended for managing chronic obstructive pulmonary disease (COPD) symptoms like dyspnea. Current evidence does not support their use, and they carry risks of respiratory depression.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lp(a): A potentially modifiable cardiovascular risk factor.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2026
Same author

Assessing pharmacists' knowledge and practices involving dietary supplement omega-3 fatty acids.

Journal of clinical lipidology·2025
Same author

Drug Interactions With Excessive Daytime Sleepiness Treatments.

The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians·2025
Same author

A narrative review of drugs targeting inflammation in vascular disease.

Postgraduate medicine·2025
Same author

A Clinicians Guide to Recommending Common Cholesterol-Lowering Dietary Supplements.

American journal of cardiovascular drugs : drugs, devices, and other interventions·2024
Same author

Elevated Lp(a): Guidance for Identifying and Managing Patients.

Southern medical journal·2024

Area of Science:

  • Pulmonary Medicine
  • Pharmacology

Background:

  • Chronic obstructive pulmonary disease (COPD) is a progressive lung disease characterized by persistent respiratory symptoms, including dyspnea.
  • Opioids are sometimes considered for symptom management, but their role in COPD requires careful evaluation.

Purpose of the Study:

  • To critically assess the existing literature on the efficacy and safety of nebulized opioids for managing dyspnea in patients with COPD.

Main Methods:

  • A comprehensive literature search was conducted using MEDLINE.
  • Key search terms included "nebulizer," "opioids," "COPD," "dyspnea," "morphine," and "hydromorphone."

Main Results:

  • Limited evidence exists from placebo-controlled studies to support nebulized morphine for COPD-related dyspnea relief.

Related Experiment Videos

  • Reviewed studies showed significant variability in dosage, opioid type, administration, and methodology.
  • While one small study suggested improved exercise capacity, this was not reproducible in a larger cohort. Another study indicated benefit in terminal patients, but overall, most studies found no significant benefit.

    • Conclusions:

    • Current data do not support the use of nebulized opioids in COPD management.
    • Major guidelines, such as the Global Initiative for Lung Disease, contraindicate opioids in COPD due to risks of respiratory depression and hypercapnia.
    • Nebulized opioid administration should be discouraged in patients with COPD.